Henry Schein, Inc. $HSIC Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 7.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 79,635 shares of the company’s stock after selling 6,629 shares during the quarter. PNC Financial Services Group Inc. owned about 0.07% of Henry Schein worth $5,869,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the 2nd quarter worth $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein during the second quarter valued at about $27,000. Flagship Harbor Advisors LLC acquired a new position in Henry Schein during the fourth quarter worth about $30,000. Federated Hermes Inc. acquired a new position in Henry Schein during the fourth quarter worth about $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in Henry Schein in the fourth quarter worth about $37,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $85.47 on Monday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.34. The company has a market cap of $9.74 billion, a price-to-earnings ratio of 25.82, a P/E/G ratio of 1.65 and a beta of 0.81. The business has a fifty day simple moving average of $80.98 and a 200-day simple moving average of $78.03.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The firm had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.Henry Schein’s revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the business posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HSIC. Mizuho cut their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and issued a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Morgan Stanley reissued an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Finally, BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday, June 11th. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $88.62.

Insider Buying and Selling

In other news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the acquisition, the director directly owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.